Intravenous NAD⁺ has become increasingly visible in longevity and wellness medicine.
NAD⁺ infusions are promoted for goals ranging from increased energy and recovery to improved cognitive function and healthier aging.
There is strong scientific interest in NAD⁺ biology.
But there is an important difference between studying the NAD⁺ pathway and demonstrating that intravenous NAD⁺ produces meaningful health or longevity benefits in humans.
At present, evidence for these clinical benefits is remarkably limited.
Why Is NAD⁺ Interesting for Longevity?
NAD⁺ — nicotinamide adenine dinucleotide — is essential for cellular energy metabolism and participates in DNA repair, cellular signaling and responses to metabolic stress.
Changes in NAD⁺ metabolism have been associated with aging, although the relationship differs between tissues and is more complex than a simple universal decline.
This biology has led researchers to investigate whether targeting NAD⁺ pathways could influence aspects of healthy aging.
Most human intervention research, however, has focused on oral NAD⁺ precursors such as NMN and NR, rather than intravenous NAD⁺ itself.
What Is an NAD⁺ IV Infusion?
An NAD⁺ infusion delivers NAD⁺ directly into the bloodstream through an intravenous line.
This is fundamentally different from taking NMN or NR orally.
NMN and NR are precursors that enter metabolic pathways the body can use to produce NAD⁺.
Intravenous NAD⁺ delivers NAD⁺ itself.
Evidence from one approach therefore cannot automatically be used to support another.
What Do Clinical Studies Show?
This is the critical point.
A 2026 systematic review evaluated preclinical and human evidence for NAD⁺ supplementation in anti-aging and wellness.
The researchers identified no eligible clinical outcomes studies evaluating intravenous or intramuscular NAD⁺ itself for anti-aging or wellness purposes.
A small pharmacokinetic study of intravenous NAD⁺ was identified as contextual evidence. However, it did not provide eligible clinical anti-aging outcomes.
The review also identified one nonrandomized study involving intravenous NMN. This is a different intervention and provided mainly short-term safety and biomarker information.
For anti-aging and wellness outcomes, the clinical evidence base for IV NAD⁺ itself is therefore extremely limited, with no eligible outcomes trials identified in the systematic review.
Does IV NAD⁺ Increase Energy or Improve Well-Being?
Claims surrounding NAD⁺ infusions commonly include improvements in energy, cognition and general well-being.
But biological plausibility is not the same as demonstrated clinical effectiveness.
NAD⁺ is essential for cellular energy metabolism. This does not establish that administering NAD⁺ intravenously increases a person’s energy or produces other meaningful health benefits.
In the 2026 systematic review, these claimed benefits were not established by eligible clinical outcomes trials of IV NAD⁺ itself.
Appropriate controlled human studies are needed before such effects can be considered demonstrated.
Can NAD⁺ Infusions Slow Aging?
There are currently no eligible clinical outcomes trials demonstrating that intravenous NAD⁺ slows human aging or improves healthspan.
It has not been demonstrated that IV NAD⁺:
slows biological aging,
prevents multiple age-related diseases,
extends healthspan,
or increases human lifespan.
This does not prove that IV NAD⁺ could never have clinically useful effects.
It means that these effects have not yet been demonstrated.
That distinction is important.
What About Oral NMN and NR?
Oral NMN and NR have a considerably larger human research base.
Clinical studies show that these NAD⁺ precursors can increase NAD-related metabolites in humans.
Some studies have also reported positive findings for selected functional, metabolic or physiological outcomes. However, these findings remain heterogeneous and often endpoint-specific.
Even for oral NAD⁺ precursors, current evidence does not establish that they slow overall human aging or extend healthy lifespan.
Evidence for oral NMN or NR should therefore not be used as evidence that intravenous NAD⁺ produces the same effects.
Why Does This Matter?
Longevity medicine is developing rapidly, and commercial availability can sometimes move faster than clinical research.
NAD⁺ IV therapy illustrates why the distinction between mechanism, biomarker effects and demonstrated clinical outcomes matters.
The NAD⁺ pathway is scientifically important.
NAD⁺-targeting interventions deserve continued investigation.
But evidence supporting a biological pathway should not be interpreted as proof that every intervention targeting that pathway produces meaningful clinical benefits.
